Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Functional Interplay Between Murine Leukemia Virus Glycogag, Serinc5, and Surface Glycoprotein Governs Virus Entry, with Opposite Effects on Gammaretroviral and Ebolavirus Glycoproteins.

Ahi YS, Zhang S, Thappeta Y, Denman A, Feizpour A, Gummuluru S, Reinhard B, Muriaux D, Fivash MJ, Rein A.

MBio. 2016 Nov 22;7(6). pii: e01985-16. doi: 10.1128/mBio.01985-16.

2.

Gag-dependent enrichment of HIV-1 RNA near the uropod membrane of polarized T cells.

Hatch SC, Sardo L, Chen J, Burdick R, Gorelick R, Fivash MJ Jr, Pathak VK, Hu WS.

J Virol. 2013 Nov;87(21):11912-5. doi: 10.1128/JVI.01680-13. Epub 2013 Aug 21.

3.

Matrix-assisted laser desorption/ionization mass spectrometry reveals decreased calcylcin expression in small cell lung cancer.

Lee HS, Park JW, Chertov O, Colantonio S, Simpson JT, Fivash MJ, Yoo CW, Lee GK, Zo JI, Kim HT, Kim HK.

Pathol Int. 2012 Jan;62(1):28-35. doi: 10.1111/j.1440-1827.2011.02783.x. Erratum in: Pathol Int. 2017 Sep;67(9):485.

PMID:
22192801
4.

Effects of ascorbic acid on carcinogenicity and acute toxicity of nickel subsulfide, and on tumor transplants growth in gulonolactone oxidase knock-out mice and wild-type C57BL mice.

Kasprzak KS, Diwan BA, Kaczmarek MZ, Logsdon DL, Fivash MJ, Salnikow K.

Toxicol Appl Pharmacol. 2011 Nov 15;257(1):32-7. doi: 10.1016/j.taap.2011.08.015. Epub 2011 Aug 22.

5.

Elucidation of New Binding Interactions with the Tumor Susceptibility Gene 101 (Tsg101) Protein Using Modified HIV-1 Gag-p6 Derived Peptide Ligands.

Kim SE, Liu F, Im YJ, Stephen AG, Fivash MJ, Waheed AA, Freed EO, Fisher RJ, Hurley JH, Burke TR Jr.

ACS Med Chem Lett. 2011 May 12;2(5):337-341.

6.

Recombinant origin of the retrovirus XMRV.

Paprotka T, Delviks-Frankenberry KA, Cingöz O, Martinez A, Kung HJ, Tepper CG, Hu WS, Fivash MJ Jr, Coffin JM, Pathak VK.

Science. 2011 Jul 1;333(6038):97-101. doi: 10.1126/science.1205292. Epub 2011 May 31.

7.

The DNA binding and 3'-end preferential activity of human tyrosyl-DNA phosphodiesterase.

Dexheimer TS, Stephen AG, Fivash MJ, Fisher RJ, Pommier Y.

Nucleic Acids Res. 2010 Apr;38(7):2444-52. doi: 10.1093/nar/gkp1206. Epub 2010 Jan 21.

8.

Identification of Shc Src homology 2 domain-binding peptoid-peptide hybrids.

Choi WJ, Kim SE, Stephen AG, Weidlich I, Giubellino A, Liu F, Worthy KM, Bindu L, Fivash MJ, Nicklaus MC, Bottaro DP, Fisher RJ, Burke TR Jr.

J Med Chem. 2009 Mar 26;52(6):1612-8. doi: 10.1021/jm800789h.

9.

Long-range recombination gradient between HIV-1 subtypes B and C variants caused by sequence differences in the dimerization initiation signal region.

Chin MP, Lee SK, Chen J, Nikolaitchik OA, Powell DA, Fivash MJ Jr, Hu WS.

J Mol Biol. 2008 Apr 11;377(5):1324-33. doi: 10.1016/j.jmb.2008.02.003. Epub 2008 Feb 9.

10.

Measuring the binding stoichiometry of HIV-1 Gag to very-low-density oligonucleotide surfaces using surface plasmon resonance spectroscopy.

Stephen AG, Datta SA, Worthy KM, Bindu L, Fivash MJ, Turner KB, Fabris D, Rein A, Fisher RJ.

J Biomol Tech. 2007 Sep;18(4):259-66.

11.

Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance.

Nikolenko GN, Delviks-Frankenberry KA, Palmer S, Maldarelli F, Fivash MJ Jr, Coffin JM, Pathak VK.

Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):317-22. Epub 2006 Dec 19.

12.

Nucleic acid binding and chaperone properties of HIV-1 Gag and nucleocapsid proteins.

Cruceanu M, Urbaneja MA, Hixson CV, Johnson DG, Datta SA, Fivash MJ, Stephen AG, Fisher RJ, Gorelick RJ, Casas-Finet JR, Rein A, Rouzina I, Williams MC.

Nucleic Acids Res. 2006 Jan 30;34(2):593-605. Print 2006.

13.

Complex interactions of HIV-1 nucleocapsid protein with oligonucleotides.

Fisher RJ, Fivash MJ, Stephen AG, Hagan NA, Shenoy SR, Medaglia MV, Smith LR, Worthy KM, Simpson JT, Shoemaker R, McNitt KL, Johnson DG, Hixson CV, Gorelick RJ, Fabris D, Henderson LE, Rein A.

Nucleic Acids Res. 2006 Jan 24;34(2):472-84. Print 2006. Erratum in: Nucleic Acids Res. 2006;34(3):1082.

14.

Inhibition of prolidase activity by nickel causes decreased growth of proline auxotrophic CHO cells.

Miltyk W, Surazynski A, Kasprzak KS, Fivash MJ Jr, Buzard GS, Phang JM.

J Cell Biochem. 2005 Apr 15;94(6):1210-7.

PMID:
15696600
15.
16.

A novel macrocyclic tetrapeptide mimetic that exhibits low-picomolar Grb2 SH2 domain-binding affinity.

Shi ZD, Lee K, Liu H, Zhang M, Roberts LR, Worthy KM, Fivash MJ, Fisher RJ, Yang D, Burke TR Jr.

Biochem Biophys Res Commun. 2003 Oct 17;310(2):378-83.

PMID:
14521921
17.

A high-throughput screen for identification of molecular mimics of Smac/DIABLO utilizing a fluorescence polarization assay.

Glover CJ, Hite K, DeLosh R, Scudiero DA, Fivash MJ, Smith LR, Fisher RJ, Wu JW, Shi Y, Kipp RA, McLendon GL, Sausville EA, Shoemaker RH.

Anal Biochem. 2003 Sep 15;320(2):157-69.

PMID:
12927820
18.

In vitro inhibition of the enzymatic activity of tumor suppressor FHIT gene product by carcinogenic transition metals.

Kowara R, Karaczyn AA, Fivash MJ Jr, Kasprzak KS.

Chem Res Toxicol. 2002 Mar;15(3):319-25.

PMID:
11896678
19.

Sensitivity of Escherichia coli (MutT) and human (MTH1) 8-oxo-dGTPases to in vitro inhibition by the carcinogenic metals, nickel(II), copper(II), cobalt(II) and cadmium(II).

Porter DW, Yakushiji H, Nakabeppu Y, Sekiguchi M, Fivash MJ Jr, Kasprzak KS.

Carcinogenesis. 1997 Sep;18(9):1785-91.

PMID:
9328176
20.

Mechanistic studies of the inhibition of MutT dGTPase by the carcinogenic metal Ni(II).

Porter DW, Nelson VC, Fivash MJ Jr, Kasprzak KS.

Chem Res Toxicol. 1996 Dec;9(8):1375-81.

PMID:
8951243
21.
22.

Mechanisms of nickel carcinogenesis. Interaction of Ni(II) with 2'-deoxynucleosides and 2'-deoxynucleotides.

Datta AK, Riggs CW, Fivash MJ Jr, Kasprzak KS.

Chem Biol Interact. 1991;79(3):323-34.

PMID:
1913976

Supplemental Content

Loading ...
Support Center